ACS Chemical Biology · 2016 · 34 citations · 31 references
MedicineMedicinal ChemistryOncologyMolecular OncologyMolecular PharmacologyStructural BiologyLigand BindingLigand-based DesignAnticancer ActivityP53 InactivationP53 MutationP53 Pathway AlterationsP53 Pathway DysregulationP53 Pathway InactivationStructural Basis Of DimerizationStructure-based Lead Discovery
The p53 pathway is inactivated in almost all types of cancer by mutations in the p53 encoding gene or overexpression of the p53 negative regulators, Mdm2 and/or Mdmx. Restoration of the p53 function by inhibition of the p53-Mdm2/Mdmx interaction opens up a prospect for a nongenotoxic anticancer therapy. Here, we present the syntheses, activities, and crystal structures of two novel classes of Mdm2-p53 inhibitors that are based on the 3-pyrrolin-2-one and 2-furanone scaffolds. The structures of the complexes formed by these inhibitors and Mdm2 reveal the dimeric protein molecular organization that has not been observed in the small-molecule/Mdm2 complexes described until now. In particular, the 6-chloroindole group does not occupy the usual Trp-23 pocket of Mdm2 but instead is engaged in dimerization. This entirely unique binding mode of the compounds opens new possibilities for optimization of the Mdm2-p53 interaction inhibitors.
31
NMR with Proteins and Nucleic Acids
Kurt Wüthrich · Europhysics news · 1986 · 8K citations
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Suzanne B. Shuker, Philip J. Hajduk, Robert Meadows et al. · Science · 1996 · 2K citations